



Theravance

RECEIVED  
CENTRAL FAX CENTER

AUG 17 2004

OFFICIAL

Facsimile Cover Sheet

To: Commissioner for Patents  
Attn: Examiner Shibuya, Art Unit 1639  
Company: USPTO  
Fax: (703) 872-9306

From: Jeff Hagenah  
Company: Theravance, Inc.  
Telephone: 650-808-6406  
Fax: 650-808-6078  
Date: August 17, 2004  
# of pages: 10  
(including this page)

If there are any problems in receiving this transmission, please call (650) 808-6406.

---

Comments:

Attached is a Reply for U.S. Serial No. 10/075,017.

Notice of Confidentiality

The following transmittal contains confidential information intended exclusively for the above-named person. Use, copying, distribution or disclosure of information transmitted in error is strictly prohibited. Please call Theravance, Inc. at the above number if you have received this fax in error, and either destroy or return the enclosures to us.

---

---

PRIVILEGED AND CONFIDENTIAL

---

901 Gateway Blvd., South San Francisco, CA 94080; Tel. (650) 808-6000; Fax (650) 827-8690

PTO/SB/21 (04-04)


Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/075,017	
	Filing Date	February 13, 2002	
	First Named Inventor	Jenkins et al.	
	Art Unit	1639	
	Examiner Name	Mark Lance Shibuya	
Total Number of Pages in This Submission	10	Attorney Docket Number	P-009-RC2

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>Facsimile Cover Page</b>
Remarks: The following documents are submitted: Response to Restriction Requirement (8 pages); this Transmittal page (1 page); and a Facsimile Cover page (1 page). Total = 10 pages.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Jeffrey A. Hagenah, Reg. No. 35,175
Signature	
Date	August 17, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Jeffrey A. Hagenah, Reg. No. 35,175
Signature	 Date 8/17/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9109 and select option 2.

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office at the facsimile number indicated.

Dated: August 17, 2004Facsimile Number: (703) 872-9306By: 

Jeffrey A. Hagenah, Reg. No. 35,175

PatentAttorney's Docket No. P-009-RC2

Customer No. 27038

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )

JENKINS et al. )

Group Art Unit: 1639 )

Application No.: 10/075,017 )

Examiner: Mark Lance Shibuya )

Filed: February 13, 2002 )

For: NOVEL THERAPEUTIC AGENTS )

FOR MEMBRANE TRANSPORTERS )

**RECEIVED  
CENTRAL FAX CENTER****AUG 17 2004****OFFICIAL****RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**I. INTRODUCTORY REMARKS**

These remarks are being submitted in response to the Office Action (Restriction Requirement) mailed on July 23, 2004, for the above-identified patent application. The Office Action designated a one-month period for response and therefore, this paper is due on or before August 23, 2004. Applicants have carefully considered the Office Action and hereby request reconsideration of the application in view of the following remarks.